Abstract
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age. The pathogenesis has not been fully deciphered. PCOS is associated with insulin resistance (IR), menstrual irregularities, cardiovascular disease, obesity, hirsutism, infertility, and endometrial cancer. The use of D-chiro-inositol (DCI) for the treatment of IR in PCOS has been controversial with contradictory data being published. Our objective is to evaluate the effect of DCI combined with myo-inositol (MI), and metformin on the metabolic outcomes of PCOS in a Lebanese women cohort.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Clinical Endocrinology and Metabolism
Paper Title
Journal
Date
